The Spanish pharmaceutical company Almirall SA has received a €120 million loan from the European Investment Bank (EIB) to support research into new treatments for inflammatory and dermatological diseases.
The loan is being granted under a European Commission ‘Investment Plan for Europe’ that is mobilising public funds for new technologies and employment. The company will direct the funds towards research into pathologies such as psoriasis, atopic dermatitis and actinic keratosis, a type of precancerous cutaneous lesion.